Codebreaker Labs today announced the closing of a $4.5 million seed financing led by Kickstart. The company is expanding its first-of-its-kind platform for genomic AI: empirical measurements of how individual genetic variants affect human cells, generated for tens of thousands of variants at a time. The financing will support laboratory scale-up, key scientific hires, and development of the company’s first variant Atlases and AI-powered interpretation tools.

Genomic AI needs more than DNA sequences. It needs to learn from what genetic changes actually do in human cells”

Sequencing has transformed our ability to read DNA. Understanding how genetic changes affect health remains a major challenge. Codebreaker introduces individual single-nucleotide variants into disease-relevant primary human cells and measures their individual effects at genome-scale, generating functional evidence that can strengthen variant interpretation and train more capable genomic AI models. Its approach connects computational predictions to experimental biology, closing the gap between identifying a genetic change and understanding what it does.

Read More on Fintech : Global FinTech Interview: AI and the future of fintech with Hugh Cumming, CTO, Vena

The round included continued investment from existing backers Buff Gold Ventures and Children’s Hospital Colorado, alongside participation from new investors Denver Ventures, Service Provider Capital, and Pelican Trust, an affiliate of Codebreaker Chairman Sandy Zweifach.

Codebreaker is building its first Atlas through an expanding collaboration with a leading children’s hospital. Its initial work focuses on immunology and blood cancers, with a first commercial Atlas targeted for 2027. Each Atlas will combine a curated dataset of measured variant effects with AI models trained on the data, creating a growing foundation for clinical interpretation and biomedical research based on complex genomics assays.

Source link